BioMed Research International
Volume 2015 (2015), Article ID 168935, 10 pages
http://dx.doi.org/10.1155/2015/168935

Review Article

Development of Monoclonal Antibodies in China: Overview and Prospects

Mao-Yu Zhang, Jin-Jian Lu, Liang Wang, Zi-Chao Gao, Hao Hu, Carolina Oi Lam Ung, and Yi-Tao Wang

State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau

Received 2 November 2014; Accepted 12 February 2015

Academic Editor: Michael Hust

Copyright © 2015 Mao-Yu Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Monoclonal antibodies (mAbs) have become increasingly important as human therapeutic agents. Yet, current research concentrates on technology itself and pays attention to developed countries. This paper aims to provide a comprehensive review of mAbs development in China through systematic analysis of drug registry, patent applications, clinical trials, academic publication, and ongoing R&D projects. The trends in therapeutic areas and industrialization process are also highlighted. Development and research trends of mAbs are analyzed to provide a future perspective of mAbs as therapeutic agents in China.

1. Introduction

Over the past three decades, monoclonal antibodies (mAbs) have achieved a dramatic development from scientific tools to powerful human therapeutic agents [1] (see Figure 1). Sales of mAbs therapies exceeded 40 billion US dollars in 2010 and are expected to reach 70 billion US dollars by 2015 [2]. In 1975, Kohler and Milstein firstly described the in vitro production of murine mAbs from hybridomas [3], which was an innovative step towards the development of human mAbs as therapeutic agents. In the late 1980s, clinical development of murine mAbs was initiated but then inhibited by numerous significant drawbacks [4]. Later, in attempt to overcome the inherent immunogenicity concerns and reduce effector function of murine mAbs in human [5], chimeric mouse-human antibodies were developed [6, 7]. Then, humanization antibodies were developed [8], which significantly enlarged the clinical usage of mAb. In the following research exploration, human antibodies developed by phage display [9–11] and human Ig mice advanced the development of mAb greatly [12, 13]. Nowadays, human mAbs are the fastest growing category of mAb therapeutics entering clinical study. Development of this class of therapeutic agents started as early as 1980s but achieved no clinical or commercial success until 2002 when adalimumab became the first human mAb approved by the US Food and Drug Administration (FDA) [14].

Figure 1: The development progress of antibody technology and antibody drug (date current as December 2014). Notes: 2014: Ramucirumab (VEGFR-2), Siltuximab (IL6), and Vedolizumab (α4β7). 2013: Itolizumab (CD6) [Ind], Ado-trastuzumab emtansine (HER2), and Obinutuzumab [CD20]. 2012: Pertuzumab (HER2). 2011: Belimumab (BLyS), Ipilimumab (CTLA-4), and Brentuximab (CD30), (CD25), and (TNF). 2010: Tocilizumab (IL6R) and Denosumab (RANK-L). 2009: Golimumab (TNR), Canakinumab (ILIb), Catumaxomab (EPCAM/CD3), Ustekinumab (IL12/23), and Ofatumumab (CD20). 2008: Certolizumab (TNF), (EGFR). 2007: Eculizumab (CD5). 2006: Ranibizumab (VEGF), Panitumumab (EGFR), and (HA18G/CD147). 2005: (TNF). 2004: Cetuximab (EGFR), Bevacizumab (VEGF), and Natalizumab (α-4integrin). 2003: I-Tositumomab (CD20), Omalizumab (IgE), Efalizumab (CdIIa), Alefacept (CD2), and (IL-8). 2002: Adalimumab (TNF) and In/90-Ibritumomab (CD20). 2001: Alemtuzumab (CD52). 2000: Gemtuzumab (CD33). 1999: (CD3). 1998: Basiliximab (IL2R), Palivizumab (RSV), Infliximab (TNF), Trastuzumab (HER2), and Etanercept (TNF2). 1997: Rituximab (CD20) and Daclizumab (IL2R). 1996: N/A. 1995: Edrecolomab (EPCAM). Domestic mAb product of China.

Clinical development of mAbs in China, like many developed countries, started with murine mAb [15]. R&D of mAbs in China began in the 1980s [16] and the first mAb therapeutic agent (Murine Monoclonal Antibody against Human CD3 Antigen of T Lymphocyte for Injection) was introduced in 1999 [17]. Although mAbs development in China has made significant progress over the past 2 decades [18], all the mABs currently approved by CFDA are technologically outsourced from foreign firms, like Avastin (Roche) [19]. These mAbs mainly target CD20 [20–22], antitumor necrosis factor (TNF) α [23, 24], VEGFR [25–27], HER 2 [28, 29], and EGFR [30, 31] for the treatment of cancer or immunological disorders [32]. Recently, 131I-chTNF and humanized mAb h-R3 have been developed and approved as the treatment for solid tumor after Panorex [16]. It is anticipated that continuous research on mAbs will give rise to an expanding source of therapeutics.

Stepping into 21st century, the technology level of mAbs in China has vastly improved, resulting in great research progress resulting in high expression and specificity. For example, mAbs based on research of TNFα were developed to treat rheumatoid arthritis (RA) for patients presenting with medium and severe symptoms [33]. These mAbs block the interaction between VEGF and KDR molecule and exhibit high specificity and activity [34].

This paper aims to provide a comprehensive review of mAb development in China through systematic analysis of product registry, patent application, clinical trials, academic publication, and ongoing R&D projects.

2. Method

We used multiple sources for data collection. All mAbs products approved for marketing in China were searched in the drug registry maintained by CFDA. The United States Patent and Trademark Office (USPTO) was the data source for the analysis of patent applications submitted by Chinese assignee. All clinical trials involving mAbs approved and carried out in China were identified at the Chinese Clinical Trial Registry (ChiCTR) database. Academic publications about mAbs published by researchers in mainland China were searched from Thomson Reuters’ Web of Science (WOS). Information about the progress of the ongoing R&D mAbs projects was collected from the main research institutes and firms in China. In this research, we focused primarily on the mAbs development in mainland China and thus the corresponding data about Hong Kong, Taiwan, or Macao was not considered. Based on the information from the abovementioned sources, this paper tries to present a comprehensive analysis of mAbs development in China which will help provide some perspectives for continuous development of these therapeutic agents.

3. mAbs in China

3.1. Registry of Domestic mAbs Products in China

Murine Monoclonal Antibody against Human CD3 Antigen of T Lymphocyte for Injection was the only mAb approved by CFDA since 1999 until 2003 when CFDA granted approval to the second mAb. Up to date, there are a total of eight mAb products approved by CFDA (see Table 1).

Table 1: Launched mAbs products in China.

Number
Generic
Trade
Company
Year
Therapeutic category
Target
Type
R&D
Technology source

1
Murine mAb against
Human CD3 Antigen of T Lymphocyte Injection
N/A
WIBP
1999
Treatment and prevention for acute rejection of patients received kidney and organ transplant
CD3
Murine
Me-too
Internal R&D

2
Murine mAb against
Human Interleukin-8 Cream
Enboke
Asia Space
2003
For the treatment of psoriasis vulgaris and eczema
IL-8
Murine
Me-too
Anogen-Yes, CA

3
Iodine (131I) metuximab
injection
Licartin
Chengdu Huasun
2006
For the treatment of primary liver cancer can not be resected with surgery or primary liver cancer relapse and advanced liver cancer not suitable for TACE treatment or ineffective after TACE treatment
CD147
Murine
Me-too
Fourth Military Medical University, CN

4
Iodine (131I) tumor
necrosis therapy
mAb injection
Weimeisheng
Shanghai Mei-En
2006
For the radio immunotherapy treatment of advanced lung cancer can not be controlled by radioactive chemotherapy or advanced lung cancer relapse
Intracellular DNA
Chimeric
Me-better
University Of Southern California (USC), USA

5
Nimotuzumab
injection
Taixinsheng
BioTech
2008
For the radiotherapy treatment of III/IV period of nasopharyngeal with positive expression of epidermal growth factor receptor
EGFR
Humanized
Me-better
Center of Molecular Immunology (CIM), CU

6
Recombinant Humanized Anti-CD25 mAb Injection
Jiannipai
CPGJ
2011
For the prevention of acute rejection after kidney transparent
CD25
Humanized
Me-better
Second Military Medical University, CN

7
Recombinant Human Tumor Necrosis Factor- Receptor II: IgG Fc Fusion Protein Injection
Yisaipu
CPGJ
2005
(1) For the treatment of moderate and severe active rheumatoid arthritis
(2) For the treatment of moderate and severe plaque psoriasis patients aged at least 18
(3) For the treatment of active ankylosing spondylitis.
TNF
Recombinant fusion protein
Me-better
Self-development

8
Recombinant Human
TNF Receptor-IgG Fusion Protein Injection
Qiangke
Shanghai Celgen
2011
(1) For the treatment of moderate and severe active rheumatoid arthritis
(2) For the treatment of moderate and severe plaque psoriasis patients aged at least 18
(3) For the treatment of active ankylosing spondylitis
TNF
Recombinant fusion protein
Me-too
Input from US

Notes: each row of the table represents kinds of information about mAbs products approved in China. “Trade” is brand name of drug selling in Chinese market.

“R&D Type” means that medicines are classified according to different technology and skill levels. “WIBP” is Wuhan Institute of Biological Products, Ltd.

“CPGJ” is Shanghai CP Guojian Pharmaceutical Co., Ltd.

Source: http://www.sda.gov.cn/WS01/CL0001/; author’s analysis.

3.1.1. Clinical Indications

Most of the mAbs approved as human therapeutic agents are approved for the treatment of cancer or immunological disorders [6, 35]. Of the eight mAbs launched in China, three target antigens related to antineoplastic diseases, five target antigens related to immunological diseases, and two target antigens related to kidney transplant rejection.

As shown in Table 1, there are three products approved for oncological uses including stage III/IV of nasopharyngeal carcinoma (NPC), advanced liver cancer, and non-small cell lung cancer (NSCLC). Another three products are indicated for immunological diseases, namely, psoriasis vulgaris, subacute eczema, active rheumatoid arthritis, moderate and severe plaque psoriasis, and ankylosing spondylitis. There are also products which are used to prevent rejection after organ transplantation.

3.1.2. Molecular Targets

The target of a therapeutic antibody is a major determinant of its efficacy and safety profile [14]. The eight mAbs products which are approved by CFDA target a total of seven unique antigens. These include CD147, EGFR, intracellular DNA for tumor therapy, IL-8, TNF for immunological diseases, and CD 3 and CD25 for prevention of organ rejection after transplantation. There is also one mAb which target the nucleus of tumor cells.

In terms of versions, among the eight mAbs approved in China, three are murine, one is chimeric, two are humanized and two are recombinant fusion protein. At present, there is no fully human mAb approved for marketing in China.

3.1.3. Technology Source

The development of mAb technology remains at an early stage in China. Overall, the mAbs being studied are “me-too” and “me-better” products acquired through internal and external cooperation. On one hand, drug companies and universities with sufficient capacity conducted joint R&D projects. On the other hand, mAb producers in China directly purchased the production technology from foreign countries, as demonstrated by the technology purchase actions of Shanghai Mei’en (collaborate with University of Southern California, USA) and Shanghai Celgen (transfer from Condar Co., Ltd., USA).

3.2. Patent Application about Chinese mAbs

According to the USPTO database, the first mAb-related patent in China was granted to monoclonal antibody against hepatitis E virus or its fragment with binding activity and use thereof in 2006. Notably, there are a total of nine mAb-related patents approved up to date.

Of these nine patents (see Table 2), three are related to cancer diagnosis and therapy along with four other mAbs targeting TNF, EFGR, and VEGFR. Two patents which are associated with infectious diseases focus on virus or its fragment with binding activity and use thereof. For patent assignee, academic institutions are the most common and powerful controller in China, such as the Institute of Basic Medical Sciences of Chinese Academy of Medical Sciences, Shanghai Cancer Institute, and Xiamen University.

Table 2: mAb patents of China in USPTO.

Number
  Title
IPC
Assignee
Publication date
(MM/DD/YYYY)

1
Use of DKK-1 protein in the cancer diagnosis
A61B 5/00 (20060101);
A61B 8/00 (20060101);
A61B 10/00 (20060101)
Shanghai Cancer Institute
(Shenzhen, CN)
12/27/2012

2
Monoclonal antibodies binding to avian influenza virus subtype H5 hemagglutinin and uses thereof
A61K 39/42 (20060101)
Xiamen University
(Fujian Province, CN)
12/22/2011

3
Fully human anti-TNF-alpha monoclonal antibody, preparation method, and use thereof
A61K 39/395 (20060101);
C07K 16/24 (20060101);
C12N 5/10 (20060101);
C12N 15/13 (20060101);
C12N 15/00 (20060101)
Shanghai Biomabs Pharmaceuticals Co., Ltd. (Shanghai, CN)
12/06/2012

4
Anti-EFGRv3 monoclonal antibody
A61K 39/395 (20060101);
C12P 19/34 (20060101)
Shanghai Cancer Institute
(Shanghai, CN)
02/14/2013

5
Use of DKK-1 protein in the cancer diagnosis
A61K 51/00 (20060101);
A61M 36/14 (20060101)
Shanghai Cancer Institute
(Shanghai, CN)
05/14/2009

6
Anti-VEGFR monoclonal antibody, method of making, and uses thereof
A61K 39/395 (20060101);
C07K 16/00 (20060101);
A61K 39/00 (20060101);
C07K 16/28 (20060101)
Shanghai Aosaiersi Biotech Co., Ltd.
(Shanghai, CN)
02/17/2011

7
Anti-human trail receptor DR5 monoclonal antibody (AD5-10), method thereof, and use of the same
C12P 21/08 (20060101);
C12N 5/16 (20100101);
C12N 5/07 (20100101); A61K39/395 (20060101);
C07K 16/00 (20060101)
The Institute of Basic Medical Sciences of Chinese Academy of Medical Sciences
(Beijing, CN)
04/01/2010

8
Monoclonal antibody against hepatitis E virus or its fragment with binding activity and use thereof
C12P 21/08 (20060101);
C07K 16/00 (20060101)
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (Haikou, CN)
10/19/2006

9
Method and composition for diagnosis of melanocytic lesions
G01N 33/53 (20060101); G01N 33/574 (20060101)
Shanghai CP GuoJian Pharmaceutical Co., Ltd.
(Shanghai, CN)
N/A

Notes: “IPC” is International Patent Classification. “Assignee” shows the contents of mAb patents belonging to Chinese applicants in United States Patent and Trade mark Office (USPTO).

Source: http://www.uspto.gov/.

3.3. Clinical Trials of mAbs Products in China

Data of clinical trial registry indicates that there are twelve mAbs products currently undergoing clinical studies in China which have been scheduled to complete by the end of 2013.

3.3.1. Study Phase

The stages of clinical studies for the 12 mAbs were analyzed as shown in Table 3. Four candidates are in Phase II (bevacizumab, bimotuzumab and cetuximab), three in Phase III (rituximab, infliximab and bevacizumab), and five under postmarketing surveillance (ranibizumab, metuximab and rituximab). Among these, seven were chimeric mAbs while the other five were humanized mAbs.

Table 3: Clinical trial of mAbs in China.

Number
Registry number and scientific title
mAb
Year
Applicant’s institution
Funding
Target disease
Study phase
Drug combination

1
(ChiCTR-ONC-13003646)
Function of ranibizumab intraocular injection in the control of neovascular glaucoma
Ranibizumab
2013
Qilu Hospital of Shandong University
①
Neovascular glaucoma
Post-market
No

2
(ChiCTR-RCS-13003158)
VEGF gene polymorphisms predict of bevacizumab in the treatment of advanced breast cancer research
Bevacizumab
2013
South China University of Technology
Chinese Anti-Cancer Association
Breast cancer
Phase II
No

3
(ChiCTR-ONC-12002442)
Clinical study of chemoimmunotherapy with fresh frozen plasma, high dose methylprednisolone, and rituximab for ultra-high risk chronic lymphocytic leukemia
Rituximab
2012
The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
Investigator sponsored
Ultra-high risk chronic lymphocytic leukemia
Phase III
No

4
(ChiCTR-ONRC-12002397)
Neoadjuvant chemotherapy of bevacizumab, gemcitabine, and cisplatin in stage III NSCLC
Bevacizumab
2012
The First Affiliated Hospital of Guangzhou
N/A
NSCLC
Phase II
Yes

5
(ChiCTR-ONC-12002130)
Open-Label, uncontrolled, multicenter phase II study of cisplatin and 5-Fu combined with nimotuzumab as first-line treatment in patients with untreated metastatic nasopharyngeal carcinoma
Nimotuzumab
2012
Sun Yat-Sen University
Biotech
Metastatic nasopharyngeal carcinoma
Phase II
Yes

6
(ChiCTR-TRC-11001556)
Optimization treated clinical research for I-131 metuximab injection combined with chemoembolization for HCC
Metuximab
2011
Chengdu Huasun
Chengdu Huasun
HCC
Post-market
Yes

7
(ChiCTR-TNC-11001145)
A phase II study of neoadjuvant chemotherapy and IMRT combined with cetuximab in advanced T stage of nasopharyngeal carcinoma
Cetuximab
2011
Sun Yat-Sen University
Merck
Nasopharyngeal carcinoma
Phase II
Yes

8
(ChiCTR-TRC-10001060)
Efficacy and safety of infliximab in Chinese patients with rheumatoid arthritis: double-blind, randomized, placebo-controlled trial
Infliximab
2010
Shanghai Changzheng Hospital
CPGJ
Rheumatoid arthritis
Phase III
No

9
(ChiCTR-TNC-10000798)
Rituximab in the treatment of severe lupus myelopathy: a prospective, open-label pilot trial
Rituximab
2010
Shanghai JiaoTong University, Renji Hospital
Shanghai Jiaotong University, Renji Hospital
Lupus myelopathy
Post-market
Yes

10
(ChiCTR-TNC-09000606)
Triple therapy for diabetic macular edema: intravitreal bevacizumab, triamcinolone acetonide, and macular photocoagulation
Bevacizumab
2010
N/A
Hospital of Talmologico de Sorocaba
Diabetic macular edema
Phase III
Yes

11
(ChiCTR-TNC-08000116)
Open, multicenter study of cetuximab combined with IMRT and concurrent chemotherapy of cisplatin in nasopharyngeal carcinoma
Cetuximab
2008
Sun Yat-sen University
Merck
Nasopharyngeal carcinoma
Post-market
Yes

12
(ChiCTR-TRC-08000108)
Clinical study of MabThera (Rituximab) and chemotherapy for the treatment in NHL
Rituximab
2008
Fujian Tumor Hospital
Self-supported
NHL
Post-market
Yes

Notes: “Primary Sponsor” is the experiment contract organization, “Funding” represents the resource of fund, from which institutions or others. “①” is The Independent Innovation Foundation to Universities and Colleges by Jinan Science and Technology Bureau. “NSCLC” is “non-small-cell lung cancer.” “NHL” is short for non-Hodgkin’s lymphoma. “HCC” is Hepatocellular Carcinoma. “CPGJ” is Shanghai CP Guojian Pharmaceutical Co., Ltd.

Source: http://www.chictr.org/en/.

3.3.2. Targets and Indications

Among these twelve mAb candidates, eight are studied as the treatment for cancer while the rest are tested for their use in ophthalmology and immunology. Three of the eight mAbs for cancer treatment are under review for market reassessment. The technology to develop mAbs as antitumor drugs is considered mature. For example, as the first mAb product used in non-Hodgkin’s lymphoma (NHL) therapy, Rituxan has demonstrated great achievements in both clinical setting and market share once it has been approved. mAbs for immunological diseases are mostly used to treat rheumatoid arthritis and lupus myelopathy. Rituximab which is indicated in lupus myelopathy has gained a great success in clinical application and it is now being explored further for any new indications. Although mAbs are not considered as the drug of choice in ophthalmology, they may possibly become the innovative treatment for neovascular glaucoma and diabetic macular edema as shown in Table 3.

The following examples are used to provide a holistic view of mAbs research development in China. BioTech Pharmaceutical funded the Cancer Center in the Radiology Department of Sun Yat-Sen University to conduct open and multicenter clinical research on the efficacy of cis-platinum combined with Nimotuzumab as the first line treatment of NPC. This clinical research will help shed light on the possibility of “Taixinsheng” combination therapy. Similarly, Chengdu Huasun Bio-Tech funded Fudan University to conduct intervention study to improve clinical outcomes of the combination therapy of “Licartin” and transcatheter arterial chemoembolization (TACE). These involve eight clinical trials which evaluate the clinical effectiveness of mAbs in combination therapies. This is an indication that mAbs as part of a combination therapy has become the new and alternative trend in future research.

3.4. Analysis of mAbs-Related Publications in China

Academic publications related to mAbs in China were extracted from Thomson Reuters’ Web of Science (WOS) database. This is a powerful database which contains bibliographic data for, and citation to, publications in over 10,000 of the world’s most important academic journals dating back to 1900. Studies and research about mAbs in China began in the 21st century [36]. Publications related to mAbs between 2000 and 2013 were searched using the following strategies: Topic = (monoclonal antibod) and Title = (monoclonal antibod) AND Address = (CHINA NOT HONGKONG NOT TAIWAN NOT MACAU). “mAbs” was used as the keyword in the same way. In the query above, the asterisk () represents any group of characters or no character and the literature type is limited in “Article.”

When “monoclonal antibody” was used as the search word, 957 articles were identified. Of these, 788 were retrieved after excluding 169 articles that were irrelevant to our research questions. With “mAb” as acronym words, 114 articles were identified. Of these, 95 articles retrieved after excluding 19 irrelevant records. Finally a total of 878 articles were collected after 5 repetitions of literature search (see Figure 2). The data shows that the number of publications was the most abundant in the last five years (2008–2013) and peaked in 2011, while the decrease in 2012 and 2013 implies the more challenges for Chinese researchers to make breakthrough in more innovative mAb research. This historical trend of research corresponded with the trends of mAbs technology development in China. By using “Result Analysis,” research areas of mAbs in China focused on biochemistry, molecular biology, immunology, biotechnology, applied microbiology, biochemical research methods, chemistry, chemical analytical, and chemistry applied. The data also showed that research in joint forces with international counterparts was a common practice in mainland China especially with the US.

Figure 2: Publication of mAbs in China (2000–2013).

3.5. Current mAbs-Related R&D Projects in China

This paper described the development and achievement of research in four main areas, namely, approved products, patent, clinical trials, and publications. In addition, research results also showed that academic institutes and enterprises play an increasingly important role in mAbs research in China. The leading R&D institutions in China are listed in Table 4.

Table 4: Chinese leading mAbs R&D institutions.

Number
R&D institutions
Ongoing
Products
Remarks

1
Academy of Military Medical Science
Gene cloning, humanized construction
Anti-tetanus antibody
At present the only state-level antibody pharmaceutical engineering research institute in China

2
Institute of Genetics and Developmental Biology, CAS
High expression and platform construction of phage antibody library technology, group sequencing to gene mapping and cloning
Antiencephalitis B mAb
N/A

3
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Humanized engineering and high expression, proteomic study of “gene-environment interactions” of esophagus cancer
N/A
Set the tumor medical research and teaching as a whole

4
Institute of Medical Biotechnology Academy of Medical Sciences and Peking Union Medical College
Molecular miniaturization and high efficient, genetic engineering fusion protein based on Lidamycin and Fab’, Fab, VH, VL
N/A
N/A

5
Shanghai Institutes for Biological Sciences, CAS
The introduction and imitation of antibody, preparation of antibody, and proteome research platform support
N/A
Shanghai R&D Public Service Platform

6
Institute Pasteur of Shanghai CAS
Gene cloning, tumor immune cure, and gene therapy which based on DC
N/A
N/A

7
Southern Medical University (former the First Military Medical University)
Tumor targeted biological treatment, applied gene chip
N/A
The first biotechnology experimental base in Guangdong province

8
Cell Engineering Research Center, the Fourth Military Medical University
Screening techniques of phage antibody libraries and optimization platform establishment
Iodine (131I) antitumor necrosis therapy injection
National cell engineering Intermediate test base, antibodies to large-scale preparation technology platform

Notes: each row of the table shows the current status of R&D in China: “Ongoing” represents research activities of the institutions focusing on mAbs. “CAS” is Chinese Academy of Sciences. “DC” is dendritic cell.

Source: author’s analysis and online source.

3.5.1. Academic R&D

The R&D institution network in Beijing is mainly associated with military background, enabling access to the upstream or moderate advancement in antibody technologies, such as Academy of Military Medical Science, Institute of Genetics and Developmental Biology, and the Fourth Military Medical University. The research and development in the area of tumor therapy is their core research objective. The success of R&D in this area relies heavily on government policies encouraging ethical achievement of gene cloning, humanized construction [37], high expression, mAbs purification [38], and platform construction of phage antibody library technology [39, 40]. As fully human mAbs are considered the most promising category of targeted therapeutic agents [41], China has also shown great interests. Academy of Military Medical Science, for instance, is dedicated to advancing the screening techniques of phage antibody libraries and optimization platform establishment necessary for the development of fully human mAbs [42].

3.5.2. Industrial R&D

Drug companies in China also play an important role in the development of mAbs, especially in biosimilars [43]. Being one of the representatives among the numerous creative and energetic mAb enterprises in China, BioTech Pharmaceutical developed and produced the first humanized mAb [44]. BioTech also formed collaboration with Cuba Center of Molecular Immunology, which is yet another example demonstrating the strong interests in international cooperation by Chinese enterprises.

The R&D institution network in Shanghai focused mainly on mAbs technology industrialization. One of the R&D companies in the Zhangjiang Hi-Tech Park is Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ) which was founded by China International Trust and Investment Corporation (CITIC) and is now coinvested by Shanghai Lansheng Guojian Pharmaceutical Co., Ltd. Contributions have been made to the R&D, pilot plant test, and industrialization of antibody based drugs like CPGJ. There are other R&D companies in the park which focus on R&D, manufacturing and marketing of high quality recombinant protein for the treatment of immune disease and neoplastic disease such as Shanghai Celgen Biopharma.

4. Conclusion and Perspectives

To summarize, mAbs play an important role as efficient agent for antitumor and immunology disease. Eight products in total are launched by CFDA currently, mainly are in chimeric and humanized types. The number of total publications has been increasing since 21st century. Nevertheless higher quality articles are needed. Concerned about the intellectual property, patents applied by Chinese assignee grow rapidly. To monitor safety and effectiveness of mAbs, enterprises give support to and fund clinical trials for antitumor and other new indications. The future for mAbs in China is promising. It should be mentioned that antibody-drug conjugates are becoming an increasingly important subclass of antibody-related cancer therapeutics and glycoengineering is being developed as a method to enhance the pharmacological properties of mAbs. China may also need to pay much more attention to these kinds of antibodies.

This paper found that mAbs have experienced the fastest growth among all human therapeutic agents in the past two decades and will continue to do so in coming years [45, 46] and presented a lot of advancements which have been achieved in China [47, 48]. Chinese biosimilar antibodies may now be approved in Europe [49]; at the same time, some of the most successful innovated biopharmaceuticals currently in the market (including recombinant insulin, human growth hormone, etc.) will see the expiration of their patents in the US over the next few years. This will provide an opportunistic market share which potentially worth 40 billion dollars for biosimilars including mAbs in China [47].

However, there are still some challenges yet to be resolved and at the top of the list would be production capability for China [50]. Firstly, there is still a lack of capacity for large-scale cell and perfusion cultivation at present [51]. To address this problem, improving the cells expression is necessary. China should attempt to work with developed countries because, comparing patent information related to US, the patents applied in both countries mainly involve three of these eight sections (section C, section A, and section G) and, as indicated by the patent search results, the mAbs research in the US encompasses a lot more fields than in China [52], especially in protein expression. Moreover, according to the data searched in WOS, US has been the strategic partner to China in R&D, which as mentioned before indicates that China should be more active to track first-edge technological research to make up the lack of capacity.

Additionally, data from IMS showed that in 2007 mAb drugs accounted for 34.4% of the worldwide total sale, but only 1.7% in China [53], which was far below the global average [16]. While limited by production capability, high price, and low recognition, mAbs in Chinese market perform not well as other countries. To change the status, actions should be taken by the government. The Chinese government is particularly supportive to universities and enterprises by ensuring reliable sources of funding for biopharmaceutical research and development. Some of the most important funding sources are National Natural Science Foundation of China, National High Technology Research and Developmental Program of China, and National Basic Research Program of China. As universities and institutions account for a significant proportion of patent applications, China is steering towards a research-oriented country in the area of mAb development. Accordingly, the government has adopted favorable policies to encourage university-industry cooperation [54]. The government also provides financial support to create and maintain a healthy environment for the biopharmaceutical industry. The inclusion of cancer treatment into the National Social Security would provide prosperous future for mAbs development in China once approved [17]. Inclusion to the medical insurance catalogues also provides another important incentive for thriving mAbs development. For example, basiliximab is listed in the medical insurance catalogues in thirteen provinces while infliximab in nine provinces. Last, measures should also be made to attract much more foreign talents to join in the R&D and benefit from technology around the world. With all of these government support and joint efforts of academic and industry, there the mAb development in China may contribute to global mAbs production and therapeutic innovation. Indeed, we strongly believe that in the near future, there will be likely a rapid growth in the development and usage of mAbs in China owing to the sustained support from government.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This work was supported by the Research Fund of University of Macau (MRG013/WYT/2013/ICMS; MYRG160 (Y1-L2)-ICMS11-HH) and the Macao Science and Technology Development Fund (074/2012/A3).

References

N. Buss and S. Henderson, “Monoclonal antibody therapeutics: history and future,” Current Opinion in Pharmacology, vol. 12, pp. 615–622, 2012.

J. H. Chon and G. Zarbis-Papastoitsis, “Advances in the production and downstream processing of antibodies,” New Biotechnology, vol. 28, no. 5, pp. 458–463, 2011.

G. Kohler and C. Milstein, “Continuous cultures of fused cells secreting antibody of predefined specificity,” Nature, vol. 256, no. 5517, pp. 495–497, 1975.

R. J. Ober, C. G. Radu, V. Ghetie, and E. S. Ward, “Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies,” International Immunology, vol. 13, no. 12, pp. 1551–1559, 2001.

W. Y. K. Hwang and J. Foote, “Immunogenicity of engineered antibodies,” Methods, vol. 36, no. 1, pp. 3–10, 2005.

J. M. Reichert, “Monoclonal antibodies as innovative therapeutics,” Current Pharmaceutical Biotechnology, vol. 9, no. 6, pp. 423–430, 2008.

S. L. Morrison, M. J. Johnson, L. A. Herzenberg, and V. T. Oi, “Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains,” Proceedings of the National Academy of Sciences of the United States of America, vol. 81, no. 21, pp. 6851–6855, 1984.

M. Verhoeyen, C. Milstein, and G. Winter, “Reshaping human antibodies: grafting an antilysozyme activity,” Science, vol. 239, no. 4847, pp. 1534–1536, 1988.

C. F. Barbas III, A. S. Kang, R. A. Lerner, and S. J. Benkovic, “Assembly of combinatorial antibody libraries on phage surfaces: the gene III site,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 18, pp. 7978–7982, 1991.

F. Breitling, S. Dubel, T. Seehaus, I. Klewinghaus, and M. Little, “A surface expression vector for antibody screening,” Gene, vol. 104, no. 2, pp. 147–153, 1991.

H. R. Hoogenboom and G. Winter, “By-passing immunisation: human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro,” Journal of Molecular Biology, vol. 227, no. 2, pp. 381–388, 1992.

A. Jakobovits, “Production of fully human antibodies by transgenic mice,” Current Opinion in Biotechnology, vol. 6, no. 5, pp. 561–566, 1995.

D. M. Fishwild, S. L. O'Donnell, T. Bengoechea et al., “High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice,” Nature Biotechnology, vol. 14, no. 7, pp. 845–851, 1996.

A. L. Nelson, E. Dhimolea, and J. M. Reichert, “Development trends for human monoclonal antibody therapeutics,” Nature Reviews Drug Discovery, vol. 9, no. 10, pp. 767–774, 2010.

Z. Chen and J. Jiang, “Monoclonal antibody—from murine to humanized,” Foreign Medical Science, vol. 23, pp. 188–189, 2000.

Y. Wang, W. Wu, Q. Li, and M. Gao, “The research progress and trend of biotech drugs in reseach years in China,” Pharmaceutical Biotechnology, vol. 20, pp. 1–11, 2013.

H. Shi, M. Chen, and Y. Shi, “Challenges and prospects for monoclonal antibodies in China,” Journal of Commercial Biotechnology, vol. 19, pp. 48–54, 2013.

X. C. Liao, “Early development of antibody therapeutics: key aspects of advancing an antibody drug from research to clinic,” Trends in Bio/Pharmaceutical Industry, vol. 5, pp. 18–23, 2009.

T. Zhang, W. Chen, D. Pu, J. Zhang, and M. Wang, “The development and trend of antibody drugs,” Chinese Journal of New Drugs, vol. 17, no. 9, pp. 713–718, 2008.

M. D. Pescovitz, “Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action,” The American Journal of Transplantation, vol. 6, no. 5 I, pp. 859–866, 2006.

G. P. Adams and L. M. Weiner, “Monoclonal antibody therapy of cancer,” Nature Biotechnology, vol. 23, no. 9, pp. 1147–1157, 2005.

M. R. Smith, “Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance,” Oncogene, vol. 22, no. 47, pp. 7359–7368, 2003.

A. Moeller and F. Emling, “Monoclonal antibodies against human tumor necrosis factor (TNF), and use there of,” 5231024, 1993

M. Allez, S. Vermeire, N. Mozziconacci et al., “The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies,” Alimentary Pharmacology and Therapeutics, vol. 31, no. 1, pp. 92–101, 2010.

K. Kanai, S. Kuwabara, S. Misawa, and T. Hattori, “Failure of treatment with anti-VEGF monoclonal antibody for long-standing POEMS syndrome,” Internal Medicine, vol. 46, no. 6, pp. 311–313, 2007.

N. Ferrara, K. J. Hillan, and W. Novotny, “Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy,” Biochemical and Biophysical Research Communications, vol. 333, no. 2, pp. 328–335, 2005.

J. Mordenti, K. Thomsen, V. Licko, H. Chen, Y. G. Meng, and N. Ferrara, “Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans,” Toxicologic Pathology, vol. 27, no. 1, pp. 14–21, 1999.

J. Baselga, J. Cortés, S.-B. Kim et al., “Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer,” The New England Journal of Medicine, vol. 366, no. 2, pp. 109–119, 2012.

J. M. Reichert, “Antibodies to watch in 2014: mid-year update,” MAbs, vol. 6, no. 4, pp. 799–802, 2014.

T. M. Brand, M. Iida, and D. L. Wheeler, “Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab,” Cancer Biology and Therapy, vol. 11, no. 9, pp. 777–792, 2011.

R. L. Ferris, E. M. Jaffee, and S. Ferrone, “Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape,” Journal of Clinical Oncology, vol. 28, no. 28, pp. 4390–4399, 2010.

M. Gu and X. Zhao, “Monoclonal antibodies—focus point of anti-tumor drugs research,” China Cancer, vol. 12, pp. 523–525, 2003.

G.-H. Gao, J. Li, H.-W. Xie, and Z. Lü, “Therapeutic effect of infliximab on moderate and severe active rheumatoid arthriti,” Journal of Southern Medical University, vol. 30, no. 4, pp. 724–726, 2010.

W.-J. Sheng, B.-Y. Shang, Q.-F. Miao, and Y.-S. Zhen, “Construction of a single-chain Fv antibody against epidermal growth factor receptor and its antitumor activity,” Chinese Pharmaceutical Journal, vol. 46, no. 18, pp. 1393–1398, 2011.

J. M. Reichert, “Which are the antibodies to watch in 2013?” MAbs, vol. 5, no. 1, pp. 1–4, 2013.

J. Tang, “Opportunities and challenges brought by monoclonal antibodies rapid development to biopharmaceutical in China,” Science and Technlogy Information, vol. 19, pp. 247–248, 2010.

Z. Zhu, S. Chakraborti, Y. He et al., “Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 29, pp. 12123–12128, 2007.

P. Gagnon, “Monoclonal antibody purification with hydroxyapatite,” New Biotechnology, vol. 25, no. 5, pp. 287–293, 2009.

J. Li, T. Sai, M. Berger et al., “Human antibodies for immunotherapy development generated via a human B cell hybridoma technology,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 10, pp. 3557–3562, 2006.

S. Kozlowski and P. Swann, “Current and future issues in the manufacturing and development of monoclonal antibodies,” Advanced Drug Delivery Reviews, vol. 58, no. 5-6, pp. 707–722, 2006.

J. Ni, “New technologies for the generation of human monoclonal antibody,” Trends in Bio/Pharmaceutical Industry, vol. 5, no. 3, pp. 3–14, 2009.

Z. Chen, “Biopharmaceutical industrialization prospect in China based on the antibodies,” Chinese Medicinal Biotechnology, vol. 2, pp. 2–5, 2007.

C. Chen, “Challenges and opportunities of monoclonal antibody manufacturing in China,” Trends in Bio/Pharmaceutical Industry, vol. 5, pp. 28–33, 2009.

D. Ju, “Development of antibody drugs in China,” Trends in Bio/Pharmaceutical Industry, vol. 5, pp. 34–39, 2009.

X.-D. Yang, J. R. F. Corvalan, P. Wang, C. M.-N. Roy, and C. G. Davis, “Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states,” Journal of Leukocyte Biology, vol. 66, no. 3, pp. 401–410, 1999.

X.-D. Yang, X.-C. Jia, J. R. F. Corvalan, P. Wang, and C. G. Davis, “Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy,” Critical Reviews in Oncology/Hematology, vol. 38, no. 1, pp. 17–23, 2001.

J. Higbee and H. Tu, “Biosimilars: challenges and promises cabs workshop on biosimilar therapeutics,” Trends in Bio/Pharmaceutical Industry, vol. 5, pp. 42–44, 2009.

S. Chhatre, C. Jones, R. Francis et al., “The integrated simulation and assessment of the impacts of process change in biotherapeutic antibody production,” Biotechnology Progress, vol. 22, no. 6, pp. 1612–1620, 2006.

A. Beck and J. M. Reichert, “Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry,” mAbs, vol. 5, no. 5, pp. 621–623, 2013.

K. J. Morrow Jr., “Advances in antibody manufacturing using mammalian cells,” Biotechnology Annual Review, vol. 13, pp. 95–113, 2007.

B. Liu, “The progress of therapeutic antibody drug and the industrial key-technology of antibody production,” China Biotechnoloty, vol. 33, pp. 132–138, 2013.

S. Cui and L. Tian, “Contrastive analysis of technology patent situation between China and US,” China Medical Biotechnology, vol. 7, pp. 389–395, 2012.

G. Yu, “The SWOT analysis of antibody therapeutics in China,” Trends in Bio/Pharmaceutical Industry, vol. 5, pp. 24–27, 2009.

L.-B. Zhou, H.-M. Yuan, S.-J. Yang, D. Xing, and F.-Y. Guo, “General situation and analysis of patent applications of monoclonal antibody in China,” Chinese Journal of New Drugs, vol. 22, no. 8, pp. 873–877, 2013.